Tag: causality reclassification AE

Causality Re-Assessment After Unblinding in Clinical Trials

September 20, 2025

Causality Re-Assessment After Unblinding in Clinical Trials Re-Assessing Causality of Adverse Events After Trial Unblinding Introduction: Why Post-Unblinding Reassessment Is Critical Blinded clinical trials are designed to minimize bias by concealing treatment allocation from both investigators and participants. While this methodology strengthens the validity of efficacy outcomes, it presents unique challenges in adverse event (AE)…

Adverse Event Reporting and Management, Causality and Severity Assessments

Causality Re-Assessment After Unblinding in Clinical Trials

September 19, 2025

digi

Causality Re-Assessment After Unblinding in Clinical Trials Re-Assessing Causality of Adverse Events After Trial Unblinding Introduction: Why Causality Must Be Revisited After Unblinding In blinded clinical trials, investigators and sponsors assess adverse event (AE) causality without knowing whether a participant received the investigational product (IP), placebo, or comparator. While this preserves study integrity, it also…

Adverse Event Reporting and Management, Causality and Severity Assessments